129 related articles for article (PubMed ID: 15004437)
1. Modulation of cortisol metabolism during treatment of acromegaly is independent of body composition and insulin sensitivity.
Frajese GV; Taylor NF; Jenkins PJ; Besser GM; Monson JP
Horm Res; 2004; 61(5):246-51. PubMed ID: 15004437
[TBL] [Abstract][Full Text] [Related]
2. Modulation of cortisol metabolism by low-dose growth hormone replacement in elderly hypopituitary patients.
Toogood AA; Taylor NF; Shalet SM; Monson JP
J Clin Endocrinol Metab; 2000 Apr; 85(4):1727-30. PubMed ID: 10770221
[TBL] [Abstract][Full Text] [Related]
3. Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies.
Moore JS; Monson JP; Kaltsas G; Putignano P; Wood PJ; Sheppard MC; Besser GM; Taylor NF; Stewart PM
J Clin Endocrinol Metab; 1999 Nov; 84(11):4172-7. PubMed ID: 10566668
[TBL] [Abstract][Full Text] [Related]
4. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
[TBL] [Abstract][Full Text] [Related]
5. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.
Trainer PJ; Drake WM; Perry LA; Taylor NF; Besser GM; Monson JP
J Clin Endocrinol Metab; 2001 Jul; 86(7):2989-92. PubMed ID: 11443156
[TBL] [Abstract][Full Text] [Related]
6. Modulation of glucocorticoid metabolism by the growth hormone - IGF-1 axis.
Agha A; Monson JP
Clin Endocrinol (Oxf); 2007 Apr; 66(4):459-65. PubMed ID: 17371460
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle.
Stewart PM; Toogood AA; Tomlinson JW
Horm Res; 2001; 56 Suppl 1():1-6. PubMed ID: 11786677
[TBL] [Abstract][Full Text] [Related]
8. The effects of growth hormone deficiency and replacement on glucocorticoid exposure in hypopituitary patients on cortisone acetate and hydrocortisone replacement.
Swords FM; Carroll PV; Kisalu J; Wood PJ; Taylor NF; Monson JP
Clin Endocrinol (Oxf); 2003 Nov; 59(5):613-20. PubMed ID: 14616886
[TBL] [Abstract][Full Text] [Related]
9. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
Turner HE; Thornton-Jones VA; Wass JA
Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
11. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.
Tsilchorozidou T; Honour JW; Conway GS
J Clin Endocrinol Metab; 2003 Dec; 88(12):5907-13. PubMed ID: 14671189
[TBL] [Abstract][Full Text] [Related]
12. Sexual dimorphism of cortisol metabolism is maintained in elderly subjects and is not oestrogen dependent.
Toogood AA; Taylor NF; Shalet SM; Monson JP
Clin Endocrinol (Oxf); 2000 Jan; 52(1):61-6. PubMed ID: 10651754
[TBL] [Abstract][Full Text] [Related]
13. 11beta-hydroxysteroid dehydrogenase activity in acromegalic patients with normal or impaired carbohydrate metabolism.
Mondok A; Varga I; Glaz E; Szucs N; Tóth M; Patocs A; Beko G; Racz K
Steroids; 2009 Sep; 74(9):725-9. PubMed ID: 19540999
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
Lima GA; Wu Z; Silva CM; Barbosa FR; Dias JS; Schrank Y; Strasburger CJ; Gadelha MR
Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028
[TBL] [Abstract][Full Text] [Related]
15. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
16. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
17. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone decreases 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue.
Mai K; Andres J; Bobbert T; Maser-Gluth C; Möhlig M; Bähr V; Pfeiffer AF; Spranger J; Diederich S
Clin Endocrinol (Oxf); 2007 Sep; 67(3):419-25. PubMed ID: 17555498
[TBL] [Abstract][Full Text] [Related]
19. [Comparison between integrated 24-hour concentrations of growth hormone, insulin-like growth factor I and prolactin in acromegalic patients treated with octreotide and patients treated with octreotide LAR].
Esposito V; Esposito D; Lo Iudice G
Minerva Endocrinol; 2001 Dec; 26(4):289-92. PubMed ID: 11782718
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of hepatic 5α-reductase and 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue is associated with hyperinsulinemia in morbidly obese patients.
Baudrand R; Domínguez JM; Carvajal CA; Riquelme A; Campino C; Macchiavello S; Bozinovic M; Morales M; Pizarro M; Solis N; Escalona A; Boza C; Arrese M; Fardella CE
Metabolism; 2011 Dec; 60(12):1775-80. PubMed ID: 21704348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
